Donanemab

Category: compound

An anti-amyloid antibody targeting pyroglutamate-modified Aβ (N3pG-Aβ) in established amyloid plaques. Approved for early Alzheimer's disease.

Mechanism Detail

Donanemab targets a modified form of amyloid-beta (N3pG-Aβ) found predominantly in established plaques rather than soluble forms. This complement-mediated and microglial phagocytic clearance approach can achieve amyloid negativity on PET in a significant portion of patients, allowing treatment discontinuation.

Clinical Status

FDA-approved (2024). TRAILBLAZER-ALZ 2 showed 35% slowing of decline in early-stage patients. ARIA risk similar to lecanemab. Treatment can be stopped once amyloid-negative.

Relevant Diseases

Relevant Therapies

Related Terms